BO-653
BO-653 is an orally active anti-atherosclerotic antioxidant that exhibits high binding affinity for LDL. BO-653 scavenges linoleic acid peroxyl radicals, inhibits lipid peroxidation during the auto-oxidation of linoleic acid, and potently suppresses LDL oxidation. BO-653 inhibits Hepatitis C Virus (HCV) replication in a concentration-dependent manner, with an IC50 of 36.0 μM against the HCV subgenomic replicon in FLR3-1 cells. BO-653 demonstrates significant anti-atherosclerotic effects in various animal models, including the Watanabe heritable hyperlipidemic rabbit. BO-653 is suitable for use in research related to atherosclerosis and Hepatitis C Virus infection.
For research use only. We do not sell to patients.
- CAS No.: 157360-23-1
- Formula: C26H44O2
- Molecular Weight:388.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
BO-653 (1f) (10 min) potently inhibits linoleic acid autoxidation in a cell-free assay with an IC50 of 4.6 μM[1].
BO-653 (24 h) inhibits both SLO‑ and CuSO4‑induced oxidation of rabbit LDL[1].
BO-653 (1, 10 μM; 24 h) potently reduces electrophoretic mobility changes in CuSO4-oxidized rabbit LDL, with 1 μM treatment resulting in mobility similar to native LDL[1].
BO-653 (1, 10 μM; 24 h) potently reduces electrophoretic mobility changes in SLO-oxidized rabbit LDL[1].
BO-653 (12-1000 μM; 72 hours) inhibits HCV replication in a concentration-dependent manner in FLR3-1 and RMT-tri cells (IC50 = 36.0 μM in FLR3-1 cells) without exhibiting cytotoxicity[2].
BO-653 (0-1000 μM; 96 hours) reduces HCV NS3 protein levels in a concentration-dependent manner in FLR3-1 cells[2].
BO-653 (72 hours) demonstrates stronger anti-HCV activity in FLR3-1 cells than both lipophilic and hydrophilic antioxidants[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:FLR3-1 and RMT-tri cells
-
Concentration:12, 37, 111, 333, 1000 μM
-
Incubation Time:72 h
-
Result:Inhibited HCV replication in a concentration-dependent manner in FLR3-1 and RMT-tri cells (IC50 = 36.0 μM in FLR3-1 cells) without exhibiting cytotoxicity.
-
Cell Line:FLR3-1 cells
-
Concentration:12, 37, 111, 333, 1000 μM
-
Incubation Time:96 h
-
Result:significantly reduced HCV NS3 protein expression in FLR3-1 cells in a concentration-dependent manner.
-
Cell Line:FLR3-1 cells
-
Concentration:111 μM
-
Incubation Time:72 h
-
Result:Reduced HCV core protein expression.
Parmacokinetics
| Species | Dose | Route | Plasma Concentration |
|---|---|---|---|
| Rabbit[1] | 250 mg/kg | p.o. | 2.22 μg/mL |
In Vivo
BO-653 (2000 mg/kg; p.o.; once daily; 14 days) shows no reduction of serum HCV RNA titer in HCV-infected chimeric uPA/SCID mice, and significantly enhances the anti-HCV effect of PEG-IFN by decreasing serum and liver HCV RNA levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 157360-23-1
-
Molecular Weight 388.63
-
Formula C26H44O2
-
SMILES
OC1=C(C(C)(C)C)C2=C(OC(CCCCC)(CCCCC)C2)C=C1C(C)(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Purity & Documentation
References
[1]. Tamura K, et al. Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. J Med Chem. 2003;46(14):3083-3093. [Content Brief]
[2]. Yasui F, et al. Synthetic lipophilic antioxidant BO-653 suppresses HCV replication. J Med Virol. 2013 Feb;85(2):241-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)